Keep the ANTISENSE THERAPEUTICS name. Diamond worked for 2 decades to build pharma appreciation of our antisense technology and the name says exactly what our company is about. Instos and analysts all know our company very well. They are all awaiting results of the Duchenne's CT next year. If, or rather when exciting DMD results are reported next year, Filippis should be able to do a great licensing deal and the SP will rocket. It will be much harder if the company has been renamed for an obscure horse. There is absolutely no benefit in changing the name to Percheron which most people have probably never heard of, and which has absolutely no association with ANP's technology, however there is clearly risk of significant damage. Now is definitely not the time for name change to a horse. Hopefully this resolution will be defeated at the AGM.
ANP Price at posting:
5.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)